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Background:Graymatter (GM) andwhitematter (WM)pathologyhas an important role in disease progression of
multiple sclerosis (MS).
Objectives:To investigate the association between the development of GMandWMpathology and clinical disease
progression in patients with clinically isolated syndrome (CIS).
Methods: This prospective, observational, 48-month follow-up study examined 210 CIS patients treated with
30 µg of intramuscular interferon beta-1a once aweek.MRI and clinical assessmentswere performed at baseline,
6, 12, 24, 36 and 48months. Associations between clinical worsening [24-weeks sustained disability progression
(SDP) and occurrence of a second clinical attack] and longitudinal changes in lesion accumulation and brain at-
rophy progression were investigated by amixed-effect model analysis after correction for multiple comparisons.
Results: SDP was observed in 32 (15.2%) CIS patients, while 146 (69.5%) were stable and 32 (15.2%) showed
sustained disability improvement. 112 CIS patients (53.3%) developed clinically deﬁniteMS (CDMS). CIS patients
who developed SDP showed increased lateral ventricle volume (p b .001), and decreased GM (p= .011) and cor-
tical (p = .001) volumes compared to patients who remained stable or improved in disability. Converters to
CDMS showed an increased rate of accumulation of number of new/enlarging T2 lesions (p b .001), decreased
whole brain (p = .007) and increased lateral ventricle (p = .025) volumes.
Conclusions: Development of GM pathology and LVV enlargement are associated with SDP. Conversion to CDMS
in patients with CIS over 48 months is dependent on the accumulation of new lesions, LVV enlargement and
whole brain atrophy progression.Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Multiple sclerosis (MS) is a chronic, demyelinating, autoimmune
disease of the central nervous system (CNS). AlthoughMSwas original-
ly considered to be a disease affecting predominantly the white matter
(WM), (Geurts et al., 2009; Zivadinov and Pirko, 2012) pathological
changes of gray matter (GM) are increasingly recognized as an impor-
tant determinant of sustained neurological disability and increased re-
lapse activity in MS patients (Fisher et al., 2008; Horakova et al., 2008;
Horakova et al., 2012; Zivadinov et al., 2013a; Zivadinov et al., 2013b).ogy, School of Medicine and
00 High St, Buffalo, NY 14203,
ss article under the CC BY-NC-ND licIt has been suggested that GM pathology occurs at all stages of the dis-
ease, including patients with clinically isolated syndrome (CIS) (Dalton
et al., 2004; Calabrese et al., 2007; Ceccarelli et al., 2008; Henry et al.,
2008; Audoin et al., 2010; Jure et al., 2010; Raz et al., 2010; Calabrese
et al., 2011; Crespy et al., 2011; Roosendaal et al., 2011; Bergsland
et al., 2012; Zivadinov et al., 2013b).
Results of previous research in CIS showed a progressive develop-
ment of global GM, but not WM atrophy, (Dalton et al., 2004; Raz
et al., 2010) and a great variability in compartmentalization of GM inju-
ry (Jure et al., 2010; Crespy et al., 2011). GM atrophy progression was
associated with severity of T2 and T1 lesion burden (Roosendaal et al.,
2011). Most importantly, GM atrophy was shown to be an independent
predictor of physical disability progression (Calabrese et al., 2011;
Crespy et al., 2011; Perez-Miralles et al., 2013) and conversion to clini-
cally deﬁnite MS (CDMS) (Calabrese et al., 2011; Zivadinov et al.,
2013b) in patients with CIS.ense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ing of the role of GM pathology in progression of MS patients from the
earliest disease stages, there are still some unanswered questions. For
example, in spite of the evidence of pre-existingmicro- andmacroscop-
ic tissue damage already in subjects with radiologically isolated syn-
drome (RIS) (De Stefano et al., 2011; Giorgio et al., 2011) it is unclear,
if there are pre-existing GM pathological processes ongoing in CIS pa-
tients before their ﬁrst clinical onset (Henry et al., 2008; Audoin et al.,
2010; Bergsland et al., 2012) or if GMpathology develops predominant-
ly after disease onset (Ceccarelli et al., 2008; Raz et al., 2010).
It is also unclearwhether GMpathology developsmore rapidly in CIS
patients who convert early to CDMS, those that presentwith dissemina-
tion in space and time, or those who develop sustained disability pro-
gression (SDP) (Calabrese et al., 2011; Zivadinov et al., 2013b). Most
importantly, the majority of the current evidence is based on the
cross-sectional (Calabrese et al., 2007; Ceccarelli et al., 2008; Audoin
et al., 2010) or longitudinal studies with limited sample size and short
follow-up in patients without the use of disease-modifying treatment
(DMT) (Dalton et al., 2004; Rocca et al., 2008; Raz et al., 2010). There-
fore, the prognostic role of GMpathology for the development of clinical
progression from disease onset remains to be elucidated (Calabrese et al.,
2011; Roosendaal et al., 2011; Perez-Miralles et al., 2013; Zivadinov et al.,
2013b).
An investigator-initiated, prospective, observational study (Bergsland
et al., 2012; Kalincik et al., 2012; Horakova et al., 2013; Kalincik et al.,
2013; Weinstock-Guttman et al., 2013a; Weinstock-Guttman et al.,
2013b; Zivadinov et al., 2013b) of early intramuscular interferon
beta-1a treatment in high-risk subjects after CIS (SET study, clin.
gov # NCT01592474) was originally conducted to determine clinical,
MR imaging, genetic, and environmental outcomes associated with
the disability progression and conversion to CDMS over 48 months.
Here, we present the extension of previous results after 48 months
of follow-up. The objective of this study was to investigate the evolu-
tion of GM atrophy and its relationship to clinical disability progres-
sion and development of CDMS.
2. Methods
2.1. Study population
The SET study included 220 CIS patients in 8 centers between the
years of 2005 and 2009, who were 18–55 years of age, enrolled within
4 months from the clinical event, had an Expanded Disability Status
Scale (EDSS) score of 3.5 or less, displayed the presence of two or
more T2-hyperintense lesions on diagnostic MRI, and had the presence
of two or more oligoclonal bands in cerebrospinal ﬂuid (CSF) obtained
at the screening visit prior to steroid treatment (Kalincik et al., 2012;
Zivadinov et al., 2013b). The exclusion criteria for this study were lack
of clinical and MRI follow-up data after baseline or pregnancy.
The study included clinical visits every 3 months for 48 months and
subsequent long-term follow-up in routine clinical practice. Disability
was assessed at baseline and every 6 months thereafter, while SDP
was determined after 24 weeks from the 48 month examination. MRI
examination was obtained at baseline, 6 months, and yearly thereafter.
All patients started the treatment at baselinewith 30mg of intramuscu-
lar interferon beta-1a once a week, which has been shown to delay con-
version to CDMS (Jacobs et al., 2000). All patients were treated with
3–5 g of methylprednisolone for the ﬁrst symptom before study entry,
and a baseline MR examination was performed at least 30 days after
steroid administration. Relapses were treated with 3–5 g of methyl-
prednisolone during the study. The treatment changes were made in
accordance with the SET study protocol: patients showing inadequate
treatment response (i.e. 2 moderate relapses or 6-month sustained
progression of one EDSS step during 12 months on treatment) or lack
of tolerance (unacceptable ﬂu-like symptoms despite symptomatic
treatment or a 3-fold increase in liver enzyme concentrations). Thestudy protocol was approved by the local ethics committees in all par-
ticipating centers, and all patients gave their informed consent.
2.2. MRI acquisition and analysis
MRI was performed with a standardized protocol on the same 1.5-T
scanner (Gyroscan; Philips Medical Systems, Best, the Netherlands).
Axial brain acquisitions included ﬂuid attenuated inversion recovery,
three-dimensional (3D) T1-weighted images, and T1 spin-echo images
before and 5min after a single injection of 0.1 mmol/kg of gadopentetate
dimeglumine. The details of the MRI sequences are provided elsewhere
(Zivadinov et al., 2013b).
All MRI scans were interpreted in a blindedmanner. Image analyses
included a cumulative number and volume of contrast enhanced (CE)
and new and enlarged T2 lesions, and analyses of changes in whole-
brain and tissue speciﬁc global and regional GM volumes (Zivadinov
et al., 2013b). All 3D T1 imageswere preprocessed using an in-house de-
veloped lesion inpainting algorithm to minimize the impact of WM le-
sions on tissue volumetric analyses. Percent changes in whole brain
(WB) volumes were obtained using the SIENA method, (Smith et al.,
2001) while for the GM, WM, cortical, and lateral ventricle volume
changes, we applied a modiﬁed SIENAX multi-time point algorithm, as
previously described (Dwyer et al., 2014a). Percentage volume changes
for the total subcortical deep gray matter (SDGM) (deﬁned as the sum
of thalamus, caudate nucleus, putamen, globus pallidus, hippocampus,
amygdala, and nucleus accumbens) and thalamus at each time point
were estimated using FMRIB3s Integrated Registration and Segmenta-
tion Tool (FIRST) (Patenaude et al., 2011; Zivadinov et al., 2013b).
All MRI analyses underwent multi-level quality control and were
reviewed by a trained operator (NB) at all critical points, and either
corrected, if possible, or excluded from further analysis. Brain and skull
extraction errors were corrected manually or by adjusting appropriate
(Brain Extraction Tool) BET parameters. For all analyses, the same
corrected brain extractions were used. In addition, we also marked as
failure any longitudinal analysis pairs producing biologically implausible
percent changes in GM, WM, or WB. Although the precise value of bio-
logical implausibility is not known and may vary by disease, for the
work described here we adopted a standardized cutoff of 5% per year
(Dwyer et al., 2014b).
2.3. Statistical analysis
All analyseswere performed by using statistical software (SPSS 16.0;
SPSS, Chicago, IL) and Statistica 10 (Statsoft, Tulsa, OK, USA). Because of
non-normality, as assessed by using the Kolmogorov–Smirnov method,
T2 and CE lesion volumes and numbers were logarithmically trans-
formed. Demographic, clinical, and MRI characteristics were compared
by using the χ2 test, Student t-test, and Mann–Whitney U test. Patients
were divided into two groups based on their progression to the CDMS
within the 48 month time period of the study. CDMS was characterized
by the development of a second clinical attack. Patients were also di-
vided into three groups based on their disability progression over
48 months of the study. SDP was deﬁned as a one-point increase on
EDSS for patients with a baseline EDSS more than 0 or an increase of
1.5 for patients with the baseline EDSS of 0 sustained over at least
24 weeks after the end of the study. EDSS sustained disability improve-
ment (SDI) was deﬁned as at least a one-point decrease in EDSS (Healy
et al., 2013). Dissemination in space and time over the 48 months
follow-up was evaluated according to the McDonald 2005 (Polman
et al., 2005) and 2010 (Polman et al., 2011) criteria.
Separate longitudinal linear or quadraticmixed-effectmodels with a
random intercept for patients, with and without interaction with time,
adjusted for age, gender, time from the ﬁrst event to baseline assess-
ment, and treatment status over the 48 month follow-up, were used
to describe temporal associations betweenMRImeasures and the devel-
opment of CDMS and change in disability status.
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ﬁrst months of the study treatment, we performed additional conﬁrma-
tory mixed-effect model analyses that excluded MRI data between
baseline and 6 months, and that used only MRI changes related to the
previous time-point (6–12, 12–24, 24–36 and 36–48 months).
In spite of assessment of normal distribution of the data and multi-
level quality control of all MRI measures, to further minimize potential
confounding effect of MRI measures with high rates of biological MRI
changes over 48 months, we excluded these data from an additional
conﬁrmatory analysis (Supplement Figs. 1 and 2).
A Benjamini–Hochberg (BH) correction with p b .05 was used to
minimize the false discovery rate.
3. Results
3.1. Baseline demographic, clinical and MRI characteristics
In this 48 month study, 210 of 220 enrolled CIS patients had the
available clinical andMRI follow-updata after baseline andwere includ-
ed in the analyses. Table 1 shows baseline demographic, clinical, and
MRI characteristics of the CIS patients, separated by conversion statusTable 1
Baseline demographic, clinical and MRI characteristics of CIS patients split by conversion
status to clinically deﬁnite MS at 48 months.
CDMS
(n = 112)
Stable CIS
(n = 98)
p-Value
No. of femalesa 79 (71%) 60 (61%) 0.155b
Age at onset in years, 27.0 ± 7.2; 26 30.1 ± 8.2; 30 b0.001
Time to baseline in days 85.4 ± 25.2; 87 78.0 ± 21.3; 73.5 0.022
EDSS at onsetc 2.4 ± 1.0; 2.0;
(0–6.0)
2.3 ± 0.9; 2.0;
(0–5.5)
0.354
EDSS at baselinec 1.8 ± 0.7; 1.5;
(0.0–3.5)
1.6 ± 0.6; 1.5;
(0.0–3.5)
0.069
MSFC at baseline 2.5 ± 0.7; 2.5 2.6 ± 0.6; 2.5 0.319
Type of onset (n)a
Optic neuritis 26 (23%) 28 (29%) 0.376b
Sensory/motor 43 (38%) 46 (47%) 0.211b
Brainstem/cerebellar 17 (15%) 10 (10%) 0.157b
Polysymptomatic 21 (19%) 14 (14%) 0.191b
No. of CE lesions 1.8 ± 4.1; 0.0 0.3 ± 0.6; 0.0 0.002d
No. of CE positivitya 41 (37%) 16 (19%) 0.009b
No. of T2 lesions 13.3 ± 9.4; 11.0 10.4 ± 6.6; 9.0 0.082d
No. of patients with ≥9 T2
lesionsa
68 (61%) 52 (53%) 0.370b
CE lesion volume 0.2 ± 0.5; 0.0 0.02 ± 0.05; 0.0 0.004d
T2 lesion volume 6.2 ± 7.0; 3.6 3.8 ± 4.0; 2.5 0.053d
Normalized WB volume 1511.6 ± 75.4;
1514.2
1498.8 ± 64.3;
1500.9
0.305
Normalized GM volume 799.7 ± 45.9;
804.4
785.6 ± 46.5;
783.6
0.087
Normalized WM volume 712.0 ± 41.2;
710.3
713.2 ± 35.0;
714.6
0.817
Normalized cortical volume 625.2 ± 37.6;
629.4
614.1 ± 39.2;
611.8
0.080
Normalized lateral
ventricle volume
35.4 ± 10.4; 33.0 36.8 ± 11.6; 34.9 0.484
Total normalized SDGM
volume
60.6 ± 43.4; 60.9 60.5 ± 39.1; 59.9 0.863
Normalized thalamus volume 20.7 ± 1.7; 20.7 20.3 ± 1.5; 20.3 0.235
Unless otherwise indicated, all data are reported as mean ± standard deviation, median,
except for EDSS, where also range is presented.
Differences between the groupswere tested byusing the Student t-test, χ2 test andMann–
Whitney rank sum test. Reported p values are adjusted by using Benjamini–Hochberg cor-
rection. In bold are presented p values b0.05.
Legend: EDSS = Expanded Disability Status Scale; MSFC =Multiple Sclerosis Functional
Composite; No=number; CE= contrast enhancing;WB=whole brain, GM=graymat-
ter; WM=white matter; SDGM= subcortical deep gray matter. Units of volume are in
milliliters.
a Data in parentheses are percentages.
b χ2 test
c Data in parentheses are ranges.
d Mann–Whitney rank sum test.at the 48 month follow-up. CIS patients who converted to CDMS were
younger than stable CIS patients (p b .001) and had an increased num-
ber of CE lesions (p= .002), CE lesion volumes (LVs) (p= .004) and CE
positivity (p = .009) (Table 1). No signiﬁcant MRI brain volume differ-
ences were found between the two groups at baseline.
3.2. Follow-up clinical and treatment characteristics
Over the 48 months follow-up, 112 of 210 patients (53.3%) experi-
enced relapses and developed CDMS. The mean time from baseline to
ﬁrst relapse was 12.6 months (median 7.5; range 0–46 months). The
mean annual relapse rate was 0.37 ± 0.47 (standard deviation).
Median EDSS score at disease onset was 2.0 (range 0.0–6.0) and 1.5
(range 0–3.5) at baseline in the whole group. At the 48 month follow-
up, the median EDSS score was 1.5 (range 0–6.5) in the CDMS group
and 1.5 (range 0–4.0) in the stable CIS group. At the 48 month follow-
up, 32 (15.2%) CIS patients had SDP, 146 (69.5%) patients were stable
and 32 (15.2%) CIS patients had SDI. At 48 months, 138 (65.7%) CIS pa-
tients fulﬁlled the 2005 McDonald criteria and 171 (81.4%) fulﬁlled the
2010McDonald criteria for dissemination in space and time. The evolu-
tion of MRI lesion and brain volumetric measures in CIS patients split by
fulﬁlling theMcDonald 2010 criteria at baseline is shown in Supplement
Table 1.
All 112 (53.3%) CDMS converters received steroid treatment for re-
lapses and 139 (66.2%) patients remained on the assigned treatment
with 30 mg of intramuscular interferon beta-1a once a week during
the 48 month follow-up. Of the 71 CIS patients who changed treatment
status, 63 (30%) switchedDMT and 8 (3.8%) discontinuedDMT.We found
signiﬁcantly higherWB(p b .001),WM(p= .003), GM(pb .001), cortical
(p b .001), SDGM (p = .006) and thalamus (p = .003) volume loss over
48months in CIS patientswho changed treatment status. Also, higher lat-
eral ventricle volume (LVV) enlargement (p b .001), number of total new
T2 lesions (p b .001), T2-LV absolute change (p = 0.01), CE-LV absolute
change (p b .001) and EDSS (p = .002) were found in these CIS patients.
However, no differences in cumulative number of new CE lesions (p =
.058) have been found between the two groups. Amore detailed descrip-
tion of the treatment characteristics is given in Table 2.
3.3. Changes in MRI outcomes according to development of CDMS status
over 48 months
A cumulative mean of 11.6 total new T2 lesions developed in the
CDMS group versus 3.4 in the stable CIS group (p b .001). Additionally,
a signiﬁcantly increased number of new (p b .001), and newly enlarging
T2 lesions (p b .001) occurred in CDMS converters (Table 2). There was
also a signiﬁcantly increased accumulation of T2- and CE-LVs (p b .038)
and increased CE positivity over the follow-up (p= .036) in CDMS con-
verters (Table 2). The mixed-effect model analysis showed a signiﬁcant
association between the development of CDMS and the accumulation of
cumulative number of total new T2 lesions (p b .001) (Fig. 1), new T2
lesions and newly enlarging T2 lesions (both p b .001), but not with ab-
solute change in T2-lesion volume (LV)(p = .292). CE positivity (p =
.221) and number of cumulative CE lesions (p = .159) over 48 months
were not related to the CDMS development in the mixed-effect model
analysis. Similar analysis, in which patients with high biological MRI
changes over 48 months were excluded, is shown in Supplement Fig. 1.
CDMS converters showed increasedWB (p= .002), GM (p= .006),
cortical (p = .007), thalamus (p = .015) and WM (p = .017) volume
loss and LVV enlargement (p = .002) over the follow-up (Table 2). In
the mixed-effect model analysis, a signiﬁcant association between the
development of CDMS and an increased rate of WB volume loss (p =
.007) and of LVV enlargement (p= .025)was detected (Fig. 1). The pro-
gression rate of thalamic (p = .118, Fig. 1), cortical (p = .211) and GM
(p = .207) volume loss was not signiﬁcant in the mixed-effect model
analysis. Similar analysis, in which patients with high biological MRI
changes over 48 months were excluded, is shown in Supplement Fig. 1.
Table 2
Evolution of MRI lesion and brain volumetric measures in CIS patients split by conversion status to clinically deﬁnite MS at 48 months.
CDMS (n = 112) Stable CIS (n = 98) p-Value
Patients changed DMT, no. ae 58 (52%) 5 (5%) b0.001b
EDSS at 4 years c 2.0 ± 1.1; 1.5;
(0.0–6.5)
1.5 ± 0.7; 1.5;
(0.0–4.0)
b0.001
MSFC at 4 years 2.5 ± 0.7; 2.3 2.4 ± 0.6; 2.3 0.379
Cumulative no. of
Total new T2 lesions 11.6 ± 18.6; 5.5 3.4 ± 4.8; 2.0 b0.001d
New T2 lesions 8.63 ± 13.6; 4.0 2.7 ± 4.3; 1.0 b0.001d
Newly enlarging T2 lesions 3.0 ± 5.8; 1.0 0.7 ± 1.3; 0.0 b0.001d
Cumulative no. of new CE lesions 2.4 ± 8.5; 0.0 0.7 ± 2.2; 0.0 0.065d
CE positivity, no. a 46 (42%) 29 (30%) 0.036b
T2 lesion volume absolute change (ml) 0.4 ± 4.7; 0.03 −0.3 ± 1.4;−0.3 0.038d
CE lesion volume absolute change (ml) −0.1 ± 0.4; 0.0 −0.004 ± 0.09; 0.0 0.009d
WB volume % change −3.0 ± 2.4;−2.7 −2.0 ± 1.6;−1.7 0.002
GM volume % change −2.8 ± 2.5;−2.6 −1.8 ± 1.8;−1.7 0.006
WM volume % change −2.1 ± 2.4;−1.7 −1.3 ± 1.8;−1.3 0.017
Cortical volume % change −3.2 ± 2.5;−2.9 −2.3 ± 1.7;−2.2 0.007
Lateral ventricle volume % change 20.3 ± 16.6; 16.6 13.2 ± 9.7; 13.2 0.002
Total normalized SDGM volume % change −4.1 ± 4.0;−3.3 −3.1 ± 2.9;−2.7 0.068
Thalamus volume % change −5.4 ± 4.5;−4.9 −3.8 ± 3.8;−2.8 0.015
Unless otherwise indicated, all data are reported as mean ± standard deviation, median, except for EDSS, where also range is presented. Differences between the groups were tested by
using the Student t-test, χ2 test and Mann–Whitney rank sum test. Reported p values are adjusted by using Benjamini–Hochberg correction. In bold are presented p values b0.05.
Legend: EDSS=ExpandedDisability Status Scale; DMT=disease-modifying treatment;MSFC=Multiple Sclerosis Functional Composite;No=number; CE=contrast enhancing;WB=
whole brain, GM= gray matter; WM=white matter; LV = lateral ventricle; SDGM= subcortical deep gray matter; ml = milliliters.
a Data in parentheses are percentages.
b χ2 test
c Data in parentheses are ranges.
d Mann–Whitney rank sum test.
e Of 71 patients who changed treatment status over the follow-up, 26 patients switched to a high-dose (44 µg) interferon beta-1a, 18 patients switched to natalizumab, 7 patients
switched to glatiramer acetate, 4 patients switched to intravenous immunoglobulin E, 3 patients switched to ﬁngolimod, 2 patients switched to subcutaneous interferon beta-1b, 2 patients
switched to alemtuzumab, one patient switched to low-dose (22 µg) interferon beta-1a, and 8 patients discontinued DMT.
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baseline and 6months showed a signiﬁcant association between the de-
velopment of CDMS and the accumulation of cumulative number ofFig. 1. Changes in lesion activity and lesion volume MRI measures by conversion status to clin
Hochberg correction to minimize for false discovery rate. A, Percentage change in whole-brain
(p b .001). C, Percentage change in thalamic volume (p = .118). D, Percentage change in lateratotal new T2 lesions (p b .001), increase of WM (p = .003) and GM
(p = .024) volume loss and LVV enlargement (p b .001) over the
follow-up. Increased WB volume loss in CDMS patients was notically deﬁnite multiple sclerosis over time. p values were adjusted by using Benjamini–
volume (p = .007). B, Cumulative number of total new and newly enlarging T2 lesions
l ventricle volume (p = .025).
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fore BH correction).
In further conﬁrmatory analysis that considered only MRI changes
related to the previous time-point and excluded MRI data between 0
and 6 months, we found a signiﬁcant association between the develop-
ment of CDMS and the accumulation of cumulative number of total new
T2 lesions (p b .001), increasedWB volume loss (p= .033) and LVV en-
largement (p = .025).
3.4. Changes in MRI outcomes according to disability status over 48 months
Table 3 and Fig. 2 show the evolution of MRI lesion and brain volu-
metric measures in CIS patients split by disability status at 48 months.
In the linearmixed-effectmodel analysis, signiﬁcantly increased LVV
enlargement (p b .001), and GM (p = .011) and cortical (p = .001)
volume loss were detected in CIS patients with SDP compared to pa-
tients who remained stable or improved in their disability status over
48 months. Similar analysis, in which patients with high biological MRI
changes over 48 months were excluded, is shown in Supplement Fig. 2.
The mixed-effect model analysis that excluded MRI data between
baseline and 6months showed signiﬁcantly increased LVV enlargement
(p= .002), and cortical (p = .002), WB (p= .014) and GM (p= .022)
volume loss in CIS patientswith SDP compared to patients who remained
stable or improved in their disability status over 48 months.
In further conﬁrmatory analysis considering MRI changes related to
the previous time-point, that excludedMRI data between0 and6months,
we did not ﬁnd any signiﬁcant relationships between MRI outcomes and
disability status.
4. Discussion
This study presents a prospective, longitudinal investigation of the
association between the progression of GM atrophy and the accumula-
tion of disability and conversion to CDMS in patients receiving weekly
interferon beta-1a treatment. To the best of our knowledge, this is the
ﬁrst follow-up study reported to date on the evolution of GM pathology
and development of SDP in a homogeneous sample of CIS patients
treated with DMT. Although previous studies have reported a rela-
tionship between physical disability and development of GM pathol-
ogy, (Dalton et al., 2004; Calabrese et al., 2007; Henry et al., 2008;
Calabrese et al., 2009; Audoin et al., 2010; Raz et al., 2010) they did
not use SDP assessment, were of limited sample size and employed
a shorter follow-up period.Table 3
Evolution of MRI lesion and brain volumetric measures in CIS patients split by sustained disab
SDP
(n = 32)
Cumulative no. of
Total new T2 lesions 10.9 ± 24.0; 3.0
New T2 lesions 7.4 ± 16.2; 2.0
New enlarging T2 lesions 3.5 ± 8.3; 1.0
Cumulative no. of new CE lesions 4.1 ± 14.6; 0.0
CE positivity, no. a 8 (24%)
T2 lesion volume absolute change (ml) 0.9 ± 6.7;−0.04
CE lesion volume absolute change (ml) −0.09 ± 0.2; 0.0
WB volume % change −3.0 ± 2.4;−2.4b
GM volume % change −2.9 ± 2.9;−2.7b
WM volume % change −2.1 ± 2.5;−1.9
Cortical volume % change −3.5 ± 2.9;−3.0b
Lateral ventricle % change 22.0 ± 17.0; 18.7b
Total normalized SDGM volume % change −3.4 ± 4.7;−2.8
Thalamus volume % change −4.8 ± 4.9;−4.1
Unless otherwise indicated, all data are reported asmean± standard deviation, median. Differe
analysis. Reported p values are adjusted by using Benjamini–Hochberg correction. In bold are
Legend: SDP= sustained disability progression; SDI= sustained disability improvement; No=
matter; SDGM= subcortical deep gray matter; ml = milliliters.
a Data in parentheses are percentages.
b p values b 0.05 for differences between SDP and stable plus SDI group in the conﬁrmatoryThemost important ﬁnding of this study suggests that SDP is associ-
ated with the development of GM atrophy in CIS patients. More specif-
ically, we have found signiﬁcantly increased GM, and cortical atrophy in
patients with SDP compared to patients who remained stable or im-
proved in their disability status over 48 months. This conﬁrms the re-
sults of previous cross-sectional (Calabrese et al., 2007; Henry et al.,
2008; Audoin et al., 2010; Jure et al., 2010) and longitudinal CIS studies,
(Dalton et al., 2004; Rocca et al., 2008; Raz et al., 2010) as well as longi-
tudinal studies performed in early relapsing–remitting MS cohorts
(Horakova et al., 2008; Calabrese et al., 2012; Zivadinov et al., 2013a;
Jacobsen et al., 2014). Our results were conﬁrmed by an additional anal-
ysis that excluded MRI measures over the ﬁrst 6 months of the study to
minimize the potential effect of pseudo-atrophy. However, further
investigation is needed to explore whether accelerated GM volume
loss in SDP patients occurring early after disease onset can be attributed
to early neurodegenerative processes or rather to greater pseudo-
atrophy reﬂecting higher inﬂammatory activity at disease onset. Given
that pseudo-atrophy occurring after DMT initialization appears to be
driven more by WM volume loss (Vidal-Jordana et al., 2013) this ques-
tion remains to be elucidated.
Based on our previous research showing a relationship between tha-
lamic atrophy and conversion to CDMS, (Zivadinov et al., 2013a) the
ﬁnding of relatively high thalamic and SDGM volume loss also in the
SDI group is unexpected. Therefore further investigation is needed to
clarify if disability progression in CIS patients depends more on cortical
rather than deep GM pathology or whether these ﬁndings were inﬂu-
enced by the low number of SDI patients. Interestingly, patients with
SDI showed the lowest cortical, GM and WB atrophy development,
which is in line with ﬁndings of milder cortical lesion burden accu-
mulation in patients with a benign MS course (Calabrese et al.,
2009; Calabrese et al., 2013). Increased LVV enlargement together
with an increased rate of brain volume loss, that was driven mostly by
global GM rather than by WM pathology in patients with SDP, was
also recently reported in MS patients over 10 years (Jacobsen et al.,
2014). Most importantly, neither accumulation of cumulative T2 or CE
lesions or their LVs were associated with development of SDP, which
further emphasizes that GM pathology plays a central role in irrevers-
ible disability progression of MS patients.
Another interesting result of this study indicates an increased rate of
WB atrophy progression and accumulation of T2 lesions in CIS patients
who converted to CDMS. In this extension of the original SET study, the
conversion to CDMS was not found to be associated with thalamus
pathology, a ﬁnding previously reported over the 2-year follow-upility progression status at 48 months.
Stable
(n = 146)
SDI
(n = 32)
6.6 ± 9.7; 3.0 9.7 ± 18.5; 3.0
5.0 ± 8.3; 2.0 7.6 ± 13.2; 2.0
1.5 ± 2.4; 0.0 2.0 ± 5.9; 0.0
1.0 ± 2.3; 0.0 1.2 ± 3.0; 0.0
55 (38%) 12 (38%)
−0.3 ± 2.5;−0.3 0.9 ± 2.8; 0.08
−0.08 ± 0.3; 0.0 −0.01 ± 0.2 0.0
−2.5 ± 1.9;−2.1 −2.1 ± 2.3;−1.5
−2.3 ± 2.0;−2.0 −1.6 ± 2.5;−1.4
−1.6 ± 2.0;−1.3 −1.8 ± 2.4;−1.2
−2.8 ± 2.0;−2.6 −2.1 ± 2.3;−2.1
16.5 ± 13.6; 14.3 13.8 ± 12.6; 11.0
−3.5 ± 3.3;−3.0 −4.5 ± 3.5;−3.9
−4.4 ± 4.0;−4.0 −5.2 ± 4.8;−4.6
nces between the SDP, stable and SDI groupswere tested by using themixed-effect model
presented p values b0.05 for differences between SDP and stable plus SDI group.
number; CE= contrast enhancing;WB=whole brain, GM=graymatter; WM=white
analysis that excluded MRI data between baseline and 6 months.
Fig. 2. Temporal changes in global and tissue-speciﬁc MRI measures by disability progression status at different time points of the study are shown as a mean ± standard error. p values
were adjusted by using Benjamini–Hochberg correction to minimize for false discovery rate. A, Percentage change in gray matter volume (p = .011). B, Percentage change in cortical
volume (p = .001). C, Percentage change in whole brain volume (p = .025). D, Percentage change in lateral ventricle volume (p b .001).
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presumably a very early marker of brain damage whose predictive
value dissolves along with disease progression and brain tissue damage
accumulation, (Minagar et al., 2013) as also reported in two recent stud-
ies (Zivadinov et al., 2013a; Jacobsen et al., 2014). Furthemore, LVV en-
largement was more advanced in CIS patients who developed SDP, as
well as in thosewho converted to CDMS. Further investigation is needed
to evaluate the pathogenesis of LVV enlargement in CIS patients, which
may be also related to altered CSF ﬂow pulsatility (Magnano et al.,
2012).
Although the use of DMThas been shown to delay disability progres-
sion and conversion to CDMS, conventional DMT has an unsatisfactory
efﬁcacy to suppress disease activity in speciﬁc subpopulations of MS pa-
tients (Havrdova et al., 2010). All CIS patients enrolled in this study
were treated with intramuscular interferon beta-1a and almost 70% of
patients remained on the assigned treatment during the 48 month
follow-up. While the use of DMT probably reduced disease progression,
it failed to prevent GM atrophy development in a considerable propor-
tion of study subjects. The results of the present study showed that CIS
patients who changed their treatment status over 48months developed
more advanced GM and WM pathology of the brain. However, it is
important to note that this ﬁndingmight be due not only to several fac-
tors, such as a more aggressive course of the disease associated with
more pronounced inﬂammation but also to a more signiﬁcant pseudo-
atrophy effect caused by switching of different DMTs used in patients
with more aggressive disease.
In this context, it has been suggested that different mechanisms lead-
ing to cortical demyelination and neurodegeneration occur independent-
ly of WM pathology (Geurts et al., 2009; Popescu and Lucchinetti, 2012;
Zivadinov and Pirko, 2012). Pathological studies have shown that GMpa-
thology in earlyMS can be attributed to both active inﬂammatory cortical
demyelination and neuronal loss following retrograde degeneration fromWM (Geurts et al., 2009; Popescu and Lucchinetti, 2012; Zivadinov and
Pirko, 2012). It was shown that meningeal inﬂammation also contributes
to cortical demyelination in early MS (Popescu and Lucchinetti, 2012). In
contrast to chronic progressive stages of MS, early MS is characterized by
highly inﬂammatory, but usually promptly resolving cortical lesions
(Popescu and Lucchinetti, 2012). However, cortical lesions in early MS
may also be associated with cortical oligodendrocyte degeneration, de-
myelination and neuronal damage (Popescu and Lucchinetti, 2012;
Zivadinov and Pirko, 2012). While cortical demyelination and neurode-
generation in the progressive stages of the disease are mainly driven by
oxidative injury, it is not fully understood whether these mechanisms
are also relevant to the early stages of the disease (Fischer et al., 2013).
However, it has been shown that excessive oxidative injurymay be relat-
ed to theMS-speciﬁc gene expression changes of molecular pathways as-
sociated with inﬂammation and oxidative stress that result in DNA
damage and alterations of regenerative mechanisms affecting glial and
neuronal cell processes in the cerebral cortex of MS patients (Fischer
et al., 2013). The present studywas limited to identifying pathophysiolog-
ical mechanisms determining brain tissue damage. Only WM focal dam-
age and global, tissue speciﬁc and regional atrophy were assessed, while
more sophisticatedMRI techniques like diffusion-tensor imaging,magne-
tization transfer imaging or magnetic resonance spectroscopy were not
applied. Hence, further research is needed to clarify the nature and extent
of GM pathology in CIS and to investigate the effect of newly introduced
DMTs on the prevention of GM pathology. In particular, future investiga-
tions of DMT should focus on the prevention of cortical and SDGMpathol-
ogy in the early stages of MS.
The strengths of this study include a large sample size, homogeneous
treatment, relatively long follow-up, frequent serial MRI assessment on
a scanner that did not undergo any changes over the follow-up and as-
sessment of SDP after 24 weeks, following the 48 month follow-up. As
compared to linear or logistic regression, the application of mixed-
318 T. Uher et al. / NeuroImage: Clinical 6 (2014) 312–319effect models analysis with and without interaction with time, adjusted
for age, gender, time from the ﬁrst event to baseline assessment, and
treatment status over the 48 month follow-up, increased the statistical
power of the study.
However, there are also limitations of the present study. The absence
of healthy controls prevented us from exploring GM atrophy progres-
sion related to normal aging. In addition, given that all CIS patients en-
tering the SET study had two or more oligoclonal bands in their CSF
and two or more hyperintense T2 lesions at disease onset, they repre-
sent a high risk population for disease progression, which limits the
generalizability of our ﬁndings to all CIS patients. Regional approaches,
including voxel-based morphometry and T2 lesion distribution proba-
bility may provide additional information in explaining the conversion
to CDMS and disability progression. In addition, it is well known that
high-dose intravenous corticosteroid (Fox et al., 2005), interferon-beta
(Hardmeier et al., 2005) or natalizumab (Vidal-Jordana et al., 2013)
treatment leads to a temporary reduction in brain volume, mainly due
to WM volume loss, (Vidal-Jordana et al., 2013) the phenomenon de-
scribed as a pseudoatrophy (Zivadinov et al., 2008). The pseudoatrophy
effect is present in the ﬁrst 3 months of the study when interferon-beta
treatment is used (Dwyer et al., 2014b). It is therefore less likely that
pseudoatrophywould have a signiﬁcant effect on brain volume changes
over 48 months in the present study. Moreover, all CIS patients were
treated with weekly intramuscular interferon beta-1a since baseline
and analyses were adjusted for treatment change. In addition, MRI
scans were performed at least 30 days after high-dose intravenous cor-
ticosteroid administrations.
In conclusion, this study showed that the development of cortical
GM atrophy is associated with the development of SDP in CIS patients
on a standard DMT. This study extends and strengthens previous evi-
dence of a strong relationship between GM pathology and disability
progression in CIS.
Supplementary data related to this article can be found online at
http://doi.dx.org/10.1016/j.nicl.2014.09.015.
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